Julia Marie Eastland - Feb 3, 2025 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
CEO & President, Director
Signature
/s/ Andrea Paul, attorney-in-fact for Julia Marie Eastland
Stock symbol
ZNTL
Transactions as of
Feb 3, 2025
Transactions value $
$0
Form type
4
Date filed
2/5/2025, 06:29 PM
Previous filing
Feb 4, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Award $0 +59.4K +208.38% $0.00 87.9K Feb 3, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZNTL Stock Option (Right to Buy) Award $0 +59.4K $0.00 59.4K Feb 3, 2025 Common Stock 59.4K $1.68 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a two year period following the grant date, subject to the Reporting Person's continued service with the Issuer.
F2 The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.